NCI-H441 cells were derived from the papillary
adenocarcinoma of a human male patient and constitute an epithelial cell line
that is one of the foremost models researchers have for investigating the
efficacy of inhalant-based cancer therapies. With delivery to the lungs much
easier through airways in the human body, novel treatments may focus on
delivering nucleic acids in non-cytotoxic transfection
reagents to alveoli and other lung cells. NCI-H441 cells are known for
doubling in population size under sixty hours, and express the major surfactant
apoprotein, making them a unique environment for drug testing, lung cancer
research, and siRNA screening for the development of gene therapies targeting
late-stage lung cancer.
Altogen Biosystems is a quality provider and research corporation for biological laboratories. Custom biological services and supplementary preclinical items include siRNA screening, cell transfection optimization, quick cell line generation, liposome encapsulation and more. Dedicated to benefiting customers with useful and excellent services, Altogen Biosystems aims to advance modern pharmaceutical technologies. Visit Altogen for a comprehensive assortment of lung cancer xenograft models and related tools for biomedical research.
Comments
Post a Comment